Novartis

Surface Oncology appoints Detlev Biniszkiewicz CEO

Monday, May 11, 2015 09:09 AM

Surface Oncology, a Cambridge, Mass.-based provider of next-generation cancer immunotherapies, has appointed Detlev Biniszkiewicz, Ph.D., president and CEO, effective immediately. Biniszkiewicz brings over 15 years of industry leadership and experience building a transformative pipeline of novel cancer therapies, most recently as the head of the oncology strategy at AstraZeneca.

More... »

Quest Diagnostics

Two from Chiltern win Clinical Researcher of the Year

Thursday, April 30, 2015 10:36 AM

Global CRO Chiltern has earned two Clinical Researcher of the Year (CRoY) winners in the U.K., joining the five finalists previously announced from the U.S. Sarah Jones earned the Gold Pharma in the CTA category and Helen Greenleaf earned Bronze as an Aspiring CRA. Both Chiltern Source professionals are working with Novartis.

More... »


GSK to establish global vaccines R&D center in the U.S.

Monday, April 6, 2015 11:57 AM

GlaxoSmithKline is establishing a new global center for vaccines R&D in Rockville, Md. The site will become one of three global vaccines R&D centers for GSK, complementing the company’s existing global R&D center in Rixensart, Belgium and in Siena, Italy, a site GSK acquired from Novartis last month.

More... »

Aduro Biotech, Novartis collaborate on immuno-oncology products

Wednesday, April 1, 2015 12:50 PM

Aduro Biotech, a private, clinical-stage immuno-oncology company based in Berkeley, Calif., is collaborating with Novartis for the worldwide research, development and commercialization of novel immuno-oncology products derived from Aduro’s cyclic dinucleotide (CDN) approach to target the STING (Stimulator of Interferon Genes) receptor, that, when activated, is known to initiate broad innate and adaptive tumor-specific immune responses.

More... »

FDA approves first biosimilar Zarxio from Sandoz

Friday, March 6, 2015 12:24 PM

Sandoz, a Novartis company, has became the first company to receive approval of a biosimilar in the U.S. through the new FDA biosimilar pathway established under the Biologics Price Competition and Innovation Act.

More... »

Array BioPharma purchases phase III assets from Novartis

Wednesday, March 4, 2015 01:07 PM

Array BioPharma has completed both the binimetinib and encorafenib definitive agreements with Novartis. Along with global ownership of both assets, Array will receive an upfront payment of $85 million from Novartis.

More... »

GSK, Novartis complete major three-part transaction

Monday, March 2, 2015 03:03 PM

GlaxoSmithKline and Novartis have completed their three-part transaction. As a result, GSK has acquired Novartis' global vaccines business (excluding influenza vaccines) for $5.25 billion and has divested its oncology business to Novartis for $16 billion. In addition, the two have created a new consumer healthcare joint venture in which GSK will have majority control and an equity interest of 63.5%.

More... »

Adimab, Sanofi collaborate on bispecific antibodies

Monday, February 9, 2015 12:20 PM

Adimab, a Lebanon, N.H.-based technology company focused on the discovery of fully human antibodies and bispecifics, has announced a multi-target discovery and optimization collaboration with Sanofi. Adimab will use its proprietary platform to generate bispecific molecules against multiple targets. Sanofi will have the right to develop and commercialize all therapeutic antibodies and bispecifics resulting from the collaboration.

More... »

Regulatory update on GSK-Novartis three-part transaction

Thursday, January 29, 2015 12:25 PM

GlaxoSmithKline has received clearance from the European Commission (E.C.) of its proposed three-part transaction with Novartis, which includes the acquisition of Novartis’s vaccines business (excluding influenza vaccines), the creation of a consumer healthcare joint venture between GSK and Novartis and the divestment to Novartis of GSK’s marketed oncology portfolio, related R&D activities and rights to two pipeline AKT inhibitors.

More... »

Array to acquire Novartis BRAF inhibitor encorafenib (LGX818)

Friday, January 23, 2015 11:40 AM

Array BioPharma, based in Boulder, Colo., has reached a definitive agreement with Novartis Pharma to acquire worldwide rights to encorafenib (LGX818), a BRAF inhibitor currently in phase III development. This agreement is conditional on the closing of transactions announced by Novartis and GlaxoSmithKline on April 22, 2014, which are expected to close in the first half of 2015, and the agreement remains subject to the receipt of regulatory approvals.

More... »


CWWeekly

May 26

inVentiv Health aims to help sponsors prepare for new E.U. regulations on observational studies

ACRP partners with CRO Analytics to measure investigative sites' views of clinical trial quality

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

May

Job satisfaction mixed as workload increases
Salaries not keeping pace with rise in work, responsibilities

Gamification moving from early science to patient use
Pharma looking to use games for early diagnosis, recruitment, adherence

Already a subscriber?
Log in to your digital subscription.

Purchase the May issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

April

PSI, INC Research, Chiltern best with sites
Strategic outsourcing prioritizing, improving site relationships

Regulatory compliance an increasing burden on sites
Increased staff time, materials, storage eroding site operating profit

Already a subscriber?
Log in to your digital subscription.

Purchase the April issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs